Clinical Cancer Research Bridging the Lab and the Clinic in Cancer Medicine Infection and Cancer: Biology, Therapeutics, and Prevention
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, Y. J.
Right arrow Articles by Song, Y. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, Y. J.
Right arrow Articles by Song, Y. K.
Clinical Cancer Research Vol. 8, 217-220, January 2002
© 2002 American Association for Cancer Research


Experimental Therapeutics, Preclinical Pharmacology

Cooperative Interaction between Interleukin 10 and Galectin-3 against Liver Ischemia-Reperfusion Injury1

Yong J. Lee2 and Young K. Song

Department of Pharmacology, Cancer Institute, University of Pittsburgh, Pennsylvania 15213

Purpose and Experimental Design: To investigate a possible interaction between interleukin 10 (IL-10) and galectin-3 for protection of human breast carcinoma BT549 cells against liver ischemia-reperfusion-induced cytotoxicity, we used a liver/tumor coculture system. We also used IL-10-deficient C57BL/6 [IL-10(-/-)] mice and their wild-type C57BL/6 [IL-10(+/+)] mice to examine these interactions.

Results: More than 90% of galectin-3 cDNA-transfected BT549 cells (BT549-Gal3) survived after 24-h coculture with C57BL/6 [IL-10(+/+)] liver fragments isolated after ischemia. In contrast, ~70% of control vector-transfected BT549 cells (BT549-Neo) showed metabolic death after culture with liver fragment. However, when the ischemic liver from IL-10 (-/-) mice was used, BT549-Gal3 did not exhibit enhanced survival against ischemia-reperfusion-induced cytotoxicity.

Conclusions: These data suggest that IL-10 and galectin-3 cooperatively interact to protect cells from ischemia-reperfusion injury.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2002 by the American Association for Cancer Research.